Brind.

Memorial Sloan Kettering Cancer Center Presents Ovarian Cancer Trial Results

1 report, 1 independent Updated Fri 16:15
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A late-breaking oral presentation was given at ENA 2026 in Barcelona by Alison M. Schram, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center. The presentation detailed results for Rezatapopt in patients with platinum-resistant or refractory ovarian cancer. In the primary analysis population of 65 patients, the overall response rate was 48%, with a median duration of response of 10.4 months. Across all cohorts of 168 evaluable patients, the overall response rate was 36% and the median duration of response was 8.1 months.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The study results support the planned submission of the Rezatapopt New Drug Application in the first quarter of 2027. Memorial Sloan Kettering Cancer Center maintains a clinical trial partnership with Novartis, which is involved in the research and development of cancer treatments.

From manilatimes.net

Who's involved

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • NovartisSpeculative

    Novartis might see changes in revenue or investment based on the regulatory pathway and market acceptance of Rezatapopt.

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped